Top

International Journal of Colorectal Disease

Published in:

01-09-2009 | Original Article

ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery

Authors: Glauco Baiocchi, Ademar Lopes, Renata A. Coudry, Benedito M. Rossi, Fernando A. Soares, Samuel Aguiar, Gustavo C. Guimarães, Fabio O. Ferreira, Wilson T. Nakagawa

Published in: International Journal of Colorectal Disease | Issue 9/2009

Abstract

Purpose

Investigate ErbB family expression in colorectal cancer patients with higher risk of recurrence after surgical treatment.

Methods

We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique.

Results

The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis.

Conclusions

The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.

Global Cancer Facts & Figures 2007—American Cancer Society. Available from URL: http://www.cancer.org [accessed in May 14, 2008].

Nelson H, Petrelli N, Carlin A et al (2001) National Cancer Institute Expert Panel. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93(8):583–96PubMedCrossRef

Gelb AB, Schrock TR (1997) Prognostic factors in colorectal carcinomas. Surg Oncol Clin N Am 6(3):463–94PubMed

Ratto C, Sofo L, Ippoliti M et al (1998) Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 41(8):1033–49PubMedCrossRef

Compton C, Fenoglio-Preiser CM, Pettigrew N et al (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88(7):1739–57PubMedCrossRef

Greene FL, Page DL, Fleming ID et al (2002) AJCC Cancer Staging Manual—6th ed. Springer-Verlag, New YorkCrossRef

NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444–50.

Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–19PubMedCrossRef

Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–37PubMedCrossRef

10.

Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341–54PubMedCrossRef

11.

Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102(1):37–46PubMedCrossRef

12.

Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–16PubMedCrossRef

13.

Finnegan TJ, Carey LA (2007) Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 3(1):55–63PubMedCrossRef

14.

Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–87PubMedCrossRef

15.

Sergina NV, Moasser MM (2007) The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13(12):527–34 Epub 2007PubMedCrossRef

16.

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–82PubMedCrossRef

17.

Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16(6):413–28PubMedCrossRef

18.

Jeong EG, Soung YH, Lee JW et al (2006) ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer 119(12):2986–7PubMedCrossRef

19.

Karamouzis MV, Badra FA, Papavassiliou AG (2007) Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 39(5):851–6PubMedCrossRef

20.

Sartor CI, Zhou H, Kozlowska E et al (2001) Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21(13):4265–75PubMedCrossRef

21.

Compton C, Fenoglio-Preiser CM, Pettigrew N et al (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88(7):1739–57PubMedCrossRef

22.

Compton C, Fielding LP, Burgart LJ et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):979–94PubMed

23.

Kountourakis P, Pavlakis K, Psyrri A et al (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46PubMedCrossRef

24.

Jacobs TW, Gown AM, Yaziji H et al (1999) Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17(7):1983–7PubMed

25.

Yasui W, Sumiyoshi H, Hata J et al (1988) Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 48(1):137–41PubMed

26.

Spano JP, Lagorce C, Atlan D et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102–8PubMedCrossRef

27.

McKay JA, Murray LJ, Curran S et al (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38(17):2258–64PubMedCrossRef

28.

Scartozzi M, Bearzi I, Berardi R et al (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22(23):4772–8PubMedCrossRef

29.

Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92(5):1331–46PubMedCrossRef

30.

Steele RJ, Kelly P, Ellul B et al (1990) Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 77(12):1352–4PubMedCrossRef

31.

Galizia G, Lieto E, Ferraraccio F et al (2006) Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13(6):823–35PubMedCrossRef

32.

Nathanson DR, Culliford AT 4th, Shia J et al (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105(6):796–802PubMedCrossRef

33.

Schuell B, Gruenberger T, Scheithauer W et al (2006) HER 2/neu protein expression in colorectal cancer. BMC Cancer 6:123PubMedCrossRef

34.

Ochs AM, Wong L, Kakani V et al (2004) Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 4(4):262–7PubMedCrossRef

35.

McKay JA, Loane JF, Ross VG et al (2002) c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 86(4):568–73PubMedCrossRef

36.

Essapen S, Thomas H, Green M et al (2004) The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 24(2):241–8PubMed

37.

Osako T, Miyahara M, Uchino S et al (1998) Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 55(6):548–55PubMedCrossRef

38.

Kluftinger AM, Robinson BW, Quenville NF et al (1992) Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1(1):97–105PubMedCrossRef

39.

Cunningham MP, Essapen S, Thomas H et al (2006) Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28(2):329–35PubMed

40.

Maurer CA, Friess H, Kretschmann B et al (1998) Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29(8):771–7PubMedCrossRef

41.

Kapitanović S, Radosević S, Slade N et al (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126(4):205–11PubMedCrossRef

42.

Lee JC, Wang ST, Chow NH et al (2002) Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38(8):1065–71PubMedCrossRef

43.

Kountourakis P, Pavlakis K, Psyrri A et al (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46PubMedCrossRef

44.

Koumakpayi IH, Diallo JS, Le Page C et al (2006) Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12(9):2730–7PubMedCrossRef

45.

Feroz K, Williams E, Riese DJ 2nd (2002) ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cell Signal 14(9):793–8PubMedCrossRef

46.

Zlobec I, Terracciano L, Jass JR et al (2007) Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 451(4):763–9PubMedCrossRef

47.

Goethals L, Perneel C, Debucquoy A et al (2006) A new approach to the validation of tissue microarrays. J Pathol 208(5):607–14PubMedCrossRef

48.

Torhorst J, Bucher C, Kononen J et al (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159(6):2249–56PubMed

49.

Moch H, Schraml P, Bubendorf L et al (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4):981–6PubMed

Title: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery
Authors: Glauco Baiocchi
Ademar Lopes
Renata A. Coudry
Benedito M. Rossi
Fernando A. Soares
Samuel Aguiar
Gustavo C. Guimarães
Fabio O. Ferreira
Wilson T. Nakagawa
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 9/2009
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0702-6

At a glance: The STEP trials

Springer Medicine

ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2009

Subtotal colectomy with antiperistaltic cecoproctostomy for slow-transit constipation

Double rectal perforation after stapled haemorrhoidectomy

Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer

Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure

Systematic review of intraoperative colonic irrigation vs. manual decompression in obstructed left-sided colorectal emergencies

Long-term result after rubber band ligation for haemorrhoids